Frankfurt - Delayed Quote • EUR
Genetic Analysis AS (8V8.F)
At close: April 26 at 9:15 AM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
14,146.5810
14,146.5810
11,163.0180
6,799.5530
5,779.7030
Cost of Revenue
4,430.6000
4,430.6000
3,907.2710
1,281.1470
1,027.3930
Gross Profit
9,715.9810
9,715.9810
7,255.7470
5,518.4060
4,752.3100
Operating Expense
33,639.7030
33,639.7030
35,439.5000
34,389.3290
25,520.2660
Operating Income
-23,923.7220
-23,923.7220
-28,183.7530
-28,870.9230
-20,767.9560
Net Non Operating Interest Income Expense
105.8040
105.8040
-90.2860
-134.1830
-182.2870
Pretax Income
-23,817.9180
-23,817.9180
-28,274.0400
-29,005.1060
-22,135.6820
Net Income Common Stockholders
-23,817.9180
-23,817.9180
-28,274.0400
-29,005.1060
-22,135.6820
Diluted NI Available to Com Stockholders
-23,817.9180
-23,817.9180
-28,274.0400
-29,005.1060
-22,135.6820
Basic EPS
-0.62
--
-1.13
-1.15
-0.88
Diluted EPS
-0.62
--
-1.13
-1.15
-0.88
Basic Average Shares
38,415.9970
--
25,021.2740
25,216.3390
25,127.5020
Diluted Average Shares
38,415.9970
--
25,021.2740
25,216.3390
25,127.5020
Total Operating Income as Reported
--
--
--
13,378.5490
7,753.8250
Total Expenses
38,070.3030
38,070.3030
39,346.7710
35,670.4760
26,547.6590
Net Income from Continuing & Discontinued Operation
-23,817.9180
-23,817.9180
-28,274.0400
-29,005.1060
-22,135.6820
Normalized Income
-23,817.9180
-23,817.9180
-28,274.0400
-29,005.1060
-20,950.2430
Interest Income
359.4550
359.4550
27.4320
--
28.4540
Interest Expense
253.6510
253.6510
117.7180
134.1830
210.7410
Net Interest Income
105.8040
105.8040
-90.2860
-134.1830
-182.2870
EBIT
-23,564.2670
-23,564.2670
-28,156.3220
-28,870.9230
-21,924.9410
EBITDA
-17,985.5390
-17,985.5390
-23,322.7280
-24,339.8230
-15,723.7180
Reconciled Cost of Revenue
4,430.6000
4,430.6000
3,907.2710
1,281.1470
1,027.3930
Reconciled Depreciation
5,578.7280
5,578.7280
4,833.5940
4,531.1000
6,201.2230
Net Income from Continuing Operation Net Minority Interest
-23,817.9180
-23,817.9180
-28,274.0400
-29,005.1060
-22,135.6820
Total Unusual Items Excluding Goodwill
--
--
--
--
-1,185.4390
Total Unusual Items
--
--
--
--
-1,185.4390
Normalized EBITDA
-17,985.5390
-17,985.5390
-23,322.7280
-24,339.8230
-14,538.2790
12/31/2020 - 10/29/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade